Vector Consulting Group, India’s fastest-growing management consulting firm, has unveiled an in-depth analysis of recent industry developments and offers actionable insights for pharmaceutical companies to enhance agility and cost efficiency amidst dynamic challenges posed by the US market. The report provides comprehensive solutions to help companies amplify operational agility, ensure perpetual quality readiness, and build rapid research & development capabilities. By adopting these strategies, firms can enhance competitiveness and ensure long-term profitability.
The report outlines several key strategies for achieving each of these these objectives, each designed to bring significant benefits to pharmaceutical companies:
- Amplify Operational Agility: To enhance operational agility, pharmaceutical companies should transition from traditional forecast-based inventory models to dynamic, constraint-based production systems. This shift allows for better responsiveness to market changes, reducing lead times by 25%-50% and inventory levels by 20%-40%. Integrating API suppliers into the supply chain with visibility and collaboration strategies further optimizes operations, leading to significant cost savings and efficiency improvements.
- Ensure Perpetual Quality Readiness: Ensuring perpetual quality readiness involves moving beyond mere inspection preparedness to embedding regulatory compliance as a daily operational norm. Standardizing quality practices across all manufacturing plants, rigorous root cause analysis (RCA) and preventive measures, can reduce invalid Out of Specification (OOS) incidents by more than 70% and lab incidents by 50%-70%. This proactive approach not only mitigates compliance risks but also enhances operational efficiency.
- Build Rapid Research & Development Capabilities: Building rapid research and development (R&D) capabilities in the pharmaceutical industry involves adopting project flow management principles, incorporating objective capacity definitions to stagger project introductions without overburdening the system, and implementing agile planning cycles. By following these principles along with practices like ‘full kitting’ and agile short burst planning cycles with a focus on daily execution, companies can achieve a 30%-50% reduction in R&D lead times and a 50% increase in project output.
The Indian pharmaceutical sector heavily depends on the US generic market, valued at approximately $86.9 billion, making it the largest market for Indian generic drugs. Despite its size, this market has experienced continuous price erosion due to intensified competition. However, recently, some drugs have seen price increases due to supply shortages. This uncertainty complicates market trend forecasting for companies and places them in a strategic dilemma: should they prioritize cost-cutting to maintain profitability or invest in growth opportunities to prepare for emerging market dynamics?
Dr. Shelja Jose Kuruvilla – Head of Knowledge and Research, Vector Consulting Group said, “Indian companies with a significant presence in the US generic drug market often find themselves uncomfortably oscillating between cost-cutting and growth strategies. This dilemma arises because the market experiences periods of margin pressure alongside occasional opportunities for price escalations due to supply scarcity. Currently, certain drugs are defying the general trend of price erosion by increasing in price due to supply shortages. This caught some firms off guard, as they had been trimming capacity in their plants, R&D, QC, and supply chain to cut costs in response to margin pressures. Conversely, failure to optimize costs may lead to profitability issues. The solution lies in developing the ability to amplify supply chain agility significantly, rather than incrementally, while also enhancing cost efficiency.”
The Pharma Vision report provides a roadmap for pharmaceutical companies to adapt and thrive amidst market uncertainties.